Loading...

DNTH DIANTHUS THERAPEUTICS INC Product Launches 8-K Filing

DNTH

DNTH

DIANTHUS THERAPEUTICS INC

(DNTH)

2025 8-K

Financial Results Report

FDA Approval Updates

Stock Offering Agreement

Financial Results Update

Financial Update

Financial Results Announcement

Corporate Update

License Agreement Signed

Funding Agreement

Positive Trial Results

Financial Statements

Financial Statements

Financial Results

Corporate Update

Financial Results

Management Appointment

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Private Placement

Financial Results Disclosure

Reverse Stock Split and Rev...

Earnings Reports

Appointment of New Independ...

Merger and Name Change

Departure of Directors or C...

Merger Agreement

Termination of Sublease Agr...

Stockholder Rights Plan

Financial Condition and Res...

Delisting Notice

External Links:

On September 8, 2025, Dianthus Therapeutics, Inc. announced positive top-line data from the Phase 2 MaGic trial for claseprubart (DNTH103) in adults with myasthenia gravis, indicating promising results for the treatment.

AI Assistant

DIANTHUS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.